Early Access To Santheras Dmd Therapy Raxone Extended In The Uk | Latest News RSS feed

Early Access To Santheras Dmd Therapy Raxone Extended In The Uk - Latest News


Early access to Santhera’s DMD therapy Raxone extended in the UK

UK regulators have renewed the scientific opinion for Santhera’s Raxone, extending its availability to patients with Duchenne muscular dystrophy (DMD) through the Early Access to Medicines Scheme ... read more

UK patients gain early access to Duchenne drug

UK patients can gain access to Santhera’s as-yet unapproved Duchenne muscular dystrophy drug via an early access scheme. The Medicines and Healthcare products Regulatory Agency granted Raxone ... read more

Santhera facing long delay for muscular dystrophy drug in US

Santhera is facing a considerable delay in the US before it can get approval for Duchenne muscular dystrophy (DMD) candidate Raxone ... access to new therapies for the disease. In recent months the ... read more

Looking for another news?


Santhera's Raxone® Receives First Positive EAMS Scientific Opinion from UK's MHRA in Duchenne Muscular Dystrophy

Liestal, Switzerland, June 22, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that the UK`s Medicines and Healthcare products Regulatory Agency (MHRA) has granted Raxone (idebenone ... opinion ... read more


Santhera Announces Financial Results for the First Half-Year 2017 and Reports Commercial and Development Progress

Positive Early Access to ... approved Raxone for restricted use in patients with LHON. By the end of the first half-year, Santhera sold Raxone in 17 European countries. First positive EAMS Scientific ... read more

Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update

. Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Liestal, Switzerland, January 29, 2018 - Santhera Pharmaceuticals (SIX ... read more

DMD patients in the UK win early access to Santhera’s Raxone

Santhera Pharmaceuticals’ Raxone has become the first drug for Duchenne Muscular Dystrophy (DMD) to join the UK’s Early Access to Medicines Scheme (EAMS). The UK’s Medicines and Healthcare products ... read more

Santhera Pharmaceuticals Holding AG: Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update

Santhera Pharmaceuticals Holding AG / Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is ... read more

Santhera Reports Preliminary Key Financial Figures for 2016 and Provides Corporate Update

Santhera Pharmaceuticals Holding AG / Santhera Reports Preliminary Key Financial Figures for 2016 and ... the efficacy of Raxone in delaying the loss of respiratory function in DMD patients receiving ... read more

Pharma collaborates to improve chances of NICE backing Duchenne drugs

A group of pharma companies and Duchenne UK are collaborating to improve the chances of new treatments for Duchenne muscular dystrophy ... rejected Santhera’s Raxone in September, although the drug is ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us